Beijing Key Laboratory of Innovative Drug Non-clinical Drug Metabolism and PK/PD Study was approved in 2014. It is composed of key scientific researchers engaged in pharmacokinetics, pharmacology, pharmaceutical analysis and biosynthesis.
With the goal of developing innovative drugs for China's major disease spectrum and Beijing's high incidence disease spectrum, the laboratory attaches importance to the introduction and establishment of innovative theories and key technologies in international frontier fields, and takes the PK/PD research of early drug formation evaluation as the starting point to build a domestic leading non-clinical drug metabolism and PK/PD research laboratory serving Beijing and radiating the whole country, to improve China's basic and applied basic research level in this field, provide technical support for the early drug evaluation and preclinical research of new drugs in China, and promote the healthy and rapid development of Beijing and the national biomedical industry.
At present, the Key Laboratory has 31 staff members and 5 research groups. There are 10 professors, 12 associate professors.
The Laboratory has been supported by more than 50 national and local projects and foundations. It has won many scientific and technological awards such as the Chinese Medical Science and Technology Award and the Second Prize of National Science and Technology Progress Award. In the past five years, the laboratory has undertaken more than 50 technical service projects related to new drug research, among which more than 30 service projects have been completed for Beijing new drug research enterprises and institutions, accounting for more than 60% of the technical service projects.
